Clinical Trial

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Study acronym: OVERTURE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-23
Trial Details
NCT Number NCT07587515
Lead Sponsor Eyconis INC.
Conditions Neovascular (Wet) Age-Related Macular Degeneration
Enrollment 30 participants
Start Date 2026-05-19
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-07